Iovance Biotherapeutics

Iovance Biotherapeutics granted 203,980 stock options to 48 new non-executive employees on Dec 19, 2024, under its Amended and Restated 2021 Inducement Plan. Each option has an exercise price of $7.22 and vests over three years.

2024 saw significant advancements in skin cancer treatment, including FDA approvals for lifileucel and IBI363, new clinical guidelines for nonmelanoma skin cancer, an updated PDUFA date for subcutaneous nivolumab, and 3-year data for mRNA-4157 combined with pembrolizumab.

The article discusses the importance of enabling JavaScript for optimal app performance.

Iovance Biotherapeutics promotes Dr. Raj Puri to Chief Regulatory Officer, aiming to treat over 20,000 advanced melanoma patients annually by 2025.

The non-small cell lung cancer market is driven by increasing NSCLC cases, uptake of immune checkpoint inhibitors, emerging premium therapies, and awareness of mutations. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size from 2019 to 2032 in 7MM. Key companies and therapies include EMD Serono, Merck, AstraZeneca, Bristol-Myers Squibb, and therapies like M1774, C-TIL051, and Osimertinib. FDA approvals for Opdivo and Tagrisso in 2024 highlight advancements in treatment.

CRISPR Therapeutics and Iovance Biotherapeutics offer long-term investment potential. CRISPR's Casgevy and Iovance's Amtagvi are their first treatments, with significant market potential. Both companies are building treatment centers and expanding their pipelines, promising future profitability.

Iovance Biotherapeutics reports $58.6M in 3Q24 product revenue for Amtagvi™ (Lifileucel), reaffirming $160-$165M FY24 and $450-$475M FY25 guidance. European regulatory authorities validate and accept marketing authorization applications for potential approval starting in 1H2025 for the UK and 2H2025 for EU and Canada. Enrollment accelerates in IOV-LUN-202 Phase 2 trial in post-anti-PD-1 NSCLC.

Iovance Biotherapeutics to report Q3 2024 financial results on Nov 7, 2024, with a conference call at 4:30 p.m. EST. The company will also present at SITC 2024 (Nov 6-10) and Stifel 2024 Healthcare Conference (Nov 19). Abstracts for SITC include analyses of TIL products and clinical trials results.

DelveInsight's 'Melanoma Pipeline Insight 2024' covers 150+ companies and 170+ pipeline drugs, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, and BioNTech SE. Key therapies like Amtagvi (Iovance Biotherapeutics) received FDA fast-track approval in 2024 for metastatic melanoma. Neoadjuvant immunotherapy became standard care for stage III melanoma after ESMO 2024 updates. The report assesses therapies by product type, stage, route of administration, and molecule type, highlighting active and inactive pipeline products.